[Clinical outcomes of parenterally administered shuxuetong--analysis of hospital information system data].
OBJECTIVE
Hospital information system data of cerebral infaction patients who received parenterally administered Shuxuetong was analyzed. This provided frequency data regarding patients' conditions and related information in order to provide a clinical reference guide.


METHODS
In this study, HIS data from 18 hospitals was analyzed. Patients receiving parenterally administered Shuxuetong for the treatment of cerebral infarction were included. Information on age, gender, costsand route of administration were collated.


RESULTS
The average age of patients was 66 years old. Days of hospitalization ranged from 15 to 28 days. The majority of patients were classified as having phlegm and blood stasis syndrome, which is inaccordance with the indications for this drug. The most commonly used drugs used in combination with parenterally administered Shuxuetong were: aspirin, insulin and heparin.


CONCLUSIONS
Patients with cerebral infarction crowd using parenterally administered Shuxuetong were a mostly elderly population, with an average age of 66. Although generally use was in accordance with indications, dosage, and route of administration, there were however some discrepancies. Therefore, doctors need to pay close attention to guidelines and closely observe patients when using parenterally administered Shuxuetong and to consider both the clinical benefits and risks.
Institute of Basic Research in Clinical Medcine, China Academy of Medical Sciences, Beijing 100700, China. yj_zhi@126.com
Ying-Jie
YJ
Zhi
School of Statistics, Renmin University of China, Beijing 100872, China.
Hui
H
Zhang
Institute of Basic Research in Clinical Medcine, China Academy of Medical Sciences, Beijing 100700, China.
Yan-Ming
YM
Xie
Institute of Basic Research in Clinical Medcine, China Academy of Medical Sciences, Beijing 100700, China.
Wei
W
Yang
School of Statistics, Renmin University of China, Beijing 100872, China.
Hu
H
Yang
The PLA Navy General Hospital, Beijing 100048, China.
Yan
Y
Zhuang
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001241:Aspirin / Q000627:therapeutic use; D002544:Cerebral Infarction / Q000188:drug therapy*; D002648:Child; D004359:Drug Therapy, Combination; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage*; D005260:Female; D006493:Heparin / Q000627:therapeutic use; D006751:Hospital Information Systems / Q000706:statistics & numerical data*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017063:Outcome Assessment, Health Care; D064792:Pragmatic Clinical Trials as Topic; D055815:Young Adult
D004365:Drugs, Chinese Herbal; C532053:shuxuetong; D006493:Heparin; D001241:Aspirin